来自MSN3 个月
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus
a monoclonal antibody. Notably, those who received nivolumab exhibited higher rates of hepatitis B surface antigen (HBsAg) loss compared to other groups. This is seen as a significant step forward ...
GlobalData on MSN25 天
FDA breakthrough status for Bluejay’s CHD therapy brelovitug
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...
clinicaladvisor.com16 天
Brelovitug Granted Breakthrough Designation for Chronic Hepatitis Delta
Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear ...